Microbot Medical Inc. · NASDAQ:MBOT
Microbot Medical — Roth Conference (December 2016)
31 slides from Microbot Medical's conference presentation, December 2016
Slide 1: Transforming Medical Treatments Through Micro-Invasive Robotics
TRANSFORMING MEDICAL TREATMENTS THROUGH MICRO-INVASIVE ROBOTICS NASDAQ:MBOT
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS THIS DOCUMENT IS PRIVATE AND CONFIDENTIAL, CONTAINS SENSITIVE BUSINESS INFORMATION OF MICROBOT MEDICAL INC. (“MICROBOT”) AND IS NOT FOR PUBLIC DISTRIBUTION. This document has been prepared for informational purposes only and is provided personally to you. By accepting this
Slide 3: Hezi Himelfarb, General Manager & COO
TRANSFORMING MEDICAL TREATMENTS THROUGH MICRO-INVASIVE ROBOTICS HEZI HIMELFARB General Manager & COO NASDAQ:MBOT
Slide 4: The Initial Spark…
THE INITIAL SPARK... microbot
Slide 5: Evolution of Surgery…
EVOLUTION OF SURGERY… and the revolution of robotics in healthcare… Tomorrow Micro-robotics Today Robot Assisted Surgery 1990-2000 Minimally Invasive Surgery 1980-1990 Freehand Surgery 5
Slide 6: Micro-Robotics Applications
MICRO-ROBOTICS APPLICATIONS Annual review of BioMed, Micro-robots for MIS, 2010 6
Slide 7: The Next Big-Small Thing
THE NEXT BIG-SMALL THING Minimally Invasive Surgery (MIS) is one of the largest trends in surgical healthcare Global market for MIS devices in 2012 was valued at USD $25.03 Billion and is expected to reach a market value of USD $50.60 Billion by 2019. The MIS market is expected to grow at a CAGR of
Slide 8: Our Mission
OUR MISSION Enable physicians to transform medical treatments and improve patient efficacy through our micro-invasive robotic platforms
Slide 9: Investment Considerations
INVESTMENT CONSIDERATIONS Addressing multi-billion, high growth, underserved markets Developing two micro-invasive medical robotic technology platforms to enhance clinician ability to treat patients with unmet medical needs Initial neuro and GI products with comprehensive value propositions poised t
Slide 10: Technology Platforms
TECHNOLOGY PLATFORMS ViRob Autonomous Advancing Micro-Robot (AAMR) ViRob demonstrates the ability to advance within cavities similar to the typical human body's lumens TipCAT TipCAT is a disposable, flexible, self-propelled, see & treat endoscope/catheter 10
Slide 11: Sub-Platforms
PLATFORM TECHNOLOGIES PLATFORMS SUB-PLATFORMS SCS D-Stenosis TipCAT Self Cleaning Drug Delivery Diagnosis Prevention of Lumen Self Propelled Guider Shunts/Catheters Occlusion APPLICATIONS Uro Neuro GI ENT Uro Cardio Dialysis GYN Uro GI Cardio Neuro 11
Slide 12: 12
12
Slide 13: VP Shunt Market Opportunity
VP SHUNT MARKET OPPORTUNITY Hydrocephalus and Normal Pressure Hydrocephalus (NPH), are medical conditions in which there is an abnormal accumulation of cerebrospinal fluid (CSF) in the ventricles of the brain. Hydrocephalus occurs in about 1 in every 500 births in the U.S. alone 1,2 Over 1,000,000 p
Slide 14: Current Shunt Technology
CURRENT SHUNT TECHNOLOGY A shunt is a tube, usually silicon, which moves, or allows movement of, fluid from one part of the body to another Ventricular Catheter Shunt Valve Distal Catheter Shunt products have changed little since the 1950’s 14
Slide 15: Current Shunt Failure
CURRENT SHUNT FAILURE Approximately 50% of shunts in the pediatric population fail within two years of placement and repeated neurosurgical operations are often required1 Ventricular catheter blockage is by far the most frequent event2 1. Hydrocephalus Association. http://www.hydroassoc.org/complica
Slide 16: ViRob First Product: Self Cleaning Shunt (SCS)
VIROB FIRST PRODUCT Self Cleaning Shunt (SCS) A novel shunt technology for the continuous prevention of shunt blockage in hydrocephalus and NPH patients 16
Slide 17: Self Cleaning Shunt (SCS) – Lab Study
SELF CLEANING SHUNT (SCS) – LAB STUDY SCS showed the ability to prevent blockage on a shunt opening AVERAGE BLOCKAGE 100 90 Blockage percentage [%] 80 70 60 ~70% Occlusion Free 50 40 30 20 10 0 SCS 2 SCS 3 SCS 4 Ctrl 1 SCS 2 SCS 4 SCS 3 Control 1 17
Slide 18: Self Cleaning Shunt (SCS) – Lab Study
SELF CLEANING SHUNT (SCS) – LAB STUDY UK Shunt Testing Lab, Cambridge University, UK CONCLUSIONS: “Microbot Medical SCS presents low hydrodynamic resistance. The SCS behaves as a standard ventricular catheter and does not change the hydrodynamic performance of adjustable hydrocephalus valves.” 18
Slide 19: TipCAT
TipCAT Leading for Life
Slide 20: GI Endoscope Market
GI ENDOSCOPE MARKET The North American colonoscope and upper GI endoscope segments are valued at about $600 million.1 Annually, between 15 and 20 million endoscopy procedures are conducted with reusable endoscope devices to screen various components of a patient’s GI tract in the USA.2 1. North Amer
Slide 21: The Unmet Need
THE UNMET NEED Detection Rate: Cross-Contamination: The ‘GI Gap’: Approximately Named the #1 health Growing shortage 30% of polyps are technology hazard of gastroenterologists missed during Standard of 2016. The reported and increasing Colonoscopy (SC), incidence of patient volume e.g., due to polyp
Slide 22: Cross-Contamination in the News
CROSS-CONTAMINATION IN THE NEWS 22
Slide 23: First Application: Gastrointestinal Endoscopy Procedures
FIRST APPLICATION Gastrointestinal Endoscopy Procedures Colonoscopy Examining the entire colon, from the rectum to the cecum, must include the proximal colon to the splenic flexure, and it may include the terminal ileum. 23
Slide 24: The Solution
THE SOLUTION The TipCAT colonoscope innovation is driven by two proprietary concepts A Semi-disposable design: – With diagnostic and operative capabilities – Eliminate the need for cleaning / reprocessing A simple self-propulsion mechanism – Easy operation • Allows a Physician Assistant (PA)/Nurse t
Slide 25: Pre-Clinical Studies
PRE-CLINICAL STUDIES SELF-PROPELLING THROUGH 1.3M (~50 INCHES) OF A PIG’S COLON
Slide 26: Organization & Infrastructure to Execute Plan
ORGANIZATION & INFRASTRUCTURE TO EXECUTE PLAN 26
Slide 27: Robust IP Platform
ROBUST IP PLATFORM FAMILY TITLE US PATENT/APP NO. OTHER COUNTRIES US 9,061,118 Granted: EP (DE, FR, GB, IT), CA, JP, CN Tip Propelled Device for Motion Through a Passage US 14/746,660 Pending: IN US 9,427,143 Inflatable Chamber Device for Motion Through a Passage Granted: EP (DE, FR, GB, IT) US 15/2
Slide 28: Proven Leadership Team
PROVEN LEADERSHIP TEAM Prof. Moshe Shoham Harel Gadot Hezi Himelfarb Member of the Scientific Advisory Board CEO, President & Chairman GM & COO & Co-Founder Prof. Shoham is a worldwide acclaimed Mr. Gadot was formerly a Worldwide Group Mr. Himelfarb has more than 30 years of authority in the field o
Slide 29: Proven Leadership Team
PROVEN LEADERSHIP TEAM David Ben Naim Ahava Stein Simon Sharon CFO Director, Regulatory Affairs Chairman, Scientific Advisory Board Mr. Ben Naim is a CPA licensed in the State Ms. Stein, is a regulatory affairs, clinical Mr. Sharon brings 23 years of R&D and of Israel. Prior to joining Microbot Medi
Slide 30: Investment Considerations
INVESTMENT CONSIDERATIONS Addressing multi-billion, high growth, underserved markets Developing two micro-invasive medical robotic technology platforms to enhance clinician ability to treat patients with unmet medical needs Initial neuro and GI products with comprehensive value propositions poised t
Slide 31: Your Questions
YOUR QUESTIONS: Michael Polyviou EVC Group mpolyviou@evcgroup.com